Esophageal intraluminal stents with 125I seeds for advanced esophageal cancer
10.3760/cma.j.issn.1007-5232.2011.06.001
- VernacularTitle:125I粒子食管支架在晚期食管癌治疗中的价值研究
- Author:
Caili LI
;
Yue LIU
;
Zequn SUN
;
Yuan DONG
;
Yong LIU
;
Ying LIU
;
Bin WANG
- Publication Type:Journal Article
- Keywords:
Quality of life;
Advanced esophageal cancer;
Esophageal stent;
Intraluminal irradiation
- From:
Chinese Journal of Digestive Endoscopy
2011;28(6):301-304
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the therapeutic effect of esophageal intraluminal stents with 125I seeds based on survival time and quality of life (QOL) of patients with advanced esophageal cancer.Methods A total of 37 patients with advanced esophageal cancer who underwent placement of esophageal 125I irradiation stent were followed up.The QOL was evaluated by QLQ-C30 and QLQ-OES18 questionnaires before the procedure, and 1 week and 3 months after.Results The mean survival time of 37 patients was 28 weeks, with 3-month and 6-month survival rates at 94.6% (35/37) and 51.4% (19/37), respectively.Compared with the baseline, the scores of emotional functioning(EF), cognitive functioning(CF),global quality of life(QL), fatigue(FA), pain(PA), financial difficulties(FI) and pain of QLQ-OES18(OESPA) assessed 1 week after stent placement increased (P<0.05) significantly and dysphapia of QLQ-OES18(OESDYS), eating of QLQ-OES18(OESEAT), trouble swallowing saliva of QLQ-OES18(OESSV) and choked when swallowing of QLQ-OES18(OESCH) decreased significantly (P<0.05).At 3 months after stent placement, the scores of FI increased significantly (P<0.05), and those of nausea or vomiting (NV), OESDYS,OESEAT, OESSV and OESCH decreased significantly (P<0.05).The scores of FI,OESDYS, OESCH, role functioning(RF), EF,CF,FA and OESPA at 3 months were significantly different from those at 1 week after the procedure (P<0.05).Other variables at 1 week and 3 months after the procedure were not different from those before (P>0.05).Conclusion Implantation of 125I seeds combined with esophageal intraluminal stents may prolong survival time and improve QOL of patients with advanced esophageal cancer.
